We use cookies necessary to giving you a better online experience. By using our website you consent to all cookies in accordance with our Privacy Policy.
Yes, I accept
Menu
Search Opener
Copenhagen, Denmark
Onsite/Online

ESTRO 2022

Session

Urology
6018
Poster (digital)
Clinical
Detection rate of 68Ga-PSMA PET/CT from a prospective study: PSICHE trial (NCT05022914)
Giulio Francolini, Italy
PO-1363
Early toxicity and PROMS in patients receiving ultrahypofractionated PBT for prostate cancer
Lauren Evans, United Kingdom
PO-1364
SBRT for locally recurrent prostate cancer after prostatectomy and post-operative radiotherapy
Wojciech Majewski, Poland
PO-1365
THE RELATIONSHIP BETWEEN PELVIC BONE DOSE AND HEMATOTOXICITY IN PROSTATE CANCER PATIENTS
ilyas anil kilinc, Turkey
PO-1366
Salvage radiotherapy after prostatectomy for biochemical relapse
Jose Antonio Domínguez Rullán, Spain
PO-1367
Prophylactic pelvic nodal RT vs only prostate bed irradiation in patients with prostatic cancer
Taiusha Fuentes, Italy
PO-1368
Salvage SBRT re-irradiation for local recurrence of prostate cancer
Riccardo Carlo Sigillo, Italy
PO-1369
Metastasis-Directed Therapy with Cyberknife for Oligometastatic Prostate Cancer  
Sebastian Exner, Germany
PO-1370
Dose-adaptive MR-linac workflow for hypofractionated focal boost radiotherapy in prostate cancer
Linda G.W. Kerkmeijer, The Netherlands
PO-1371
Robotic stereotactic body radiotherapy for prostate cancer : an initial monoistitutional experience.
Ariadna Sanchez Galvan, Italy
PO-1372
Inter-fraction variability of rectum/bladder volumes and doses based on daily CBCT imaging
Thomas Henry, Sweden
PO-1373
Feasibility of magnetic resonance-guided adaptive post-prostatectomy radiotherapy
Vikneswary Batumalai, Australia
PO-1374
Detection of recurrence sites using FCH PET/CT in prostate cancer patients with PSA failure
Dong-Yun Kim, Korea Republic of
PO-1375
The role of Stereotactic Body Radiation Therapy in Oligometastatic Prostate Cancer
Oscar Muñoz Muñoz, Spain
PO-1376
Focal thermoablative therapy after pelvic radiotherapy for in-field prostate cancer oligo-recurrence
Nicolas Giraud, France
PO-1377
AN ALTERNATIVE SALVAGE-RADIOTHERAPY FOR RECURRENT PROSTATE CANCER AFTER LDR-BRACHYTHERAPY
Oscar Muñoz Muñoz, Spain
PO-1378
Moderate hypofractionated radiotherapy after prostatectomy in the context of the COVID19
Juan Canales, Chile
PO-1379
RESPONSE EVALUATION WITH 68GA-PSMA-PET/CT IN PROSTATE CANCER PATIENTS TREATED WITH RADIOTHERAPY
Cem Onal, Turkey
PO-1380
SBRT in prostate cancer: annalysis of CBCT guided radiotherapy and on-line correction
Jorge Olivares, Chile
PO-1381
Moderate hypofractionation for prostate cancer with fiducials markers
Jessica Guadalupe Molina Osorio, Spain
PO-1382
Adjuvant versus salvage radiotherapy in patiens with prostate cancer: a monocentric experience
Elisa Calistri, Italy
PO-1383
Simethicone use to Reduce Rectal Variability During Prostate Cancer Radiotherapy, a Randomised Trial
Jennifer Ward, Australia
PO-1384
Sleep disturbances in prostate cancer survivors one year after completing radiotherapy treatment.
Paula Blasco Valls, Spain
PO-1385
Organ preservation with tri-modality in bladder Ca- Experience from a Cancer institute in LMIC
Muneeb Uddin Karim, Pakistan
PO-1386
SBRT Boost for Intermediate and High-Risk Prostate Cancer. Results of a single Chilean institution
María Fernanda Sánchez, Chile
PO-1387
Sequential stereotactic boost in patients with macroscopic local relapse after radical prostatectomy
Flavia de Giacomo, Italy
PO-1388
BIOCHEMICAL RESPONSE AFTER STEREOTACTIC BODY RADIATION THERAPY TRAETMENT FOR PROSTATE CANCER
Jonathan Saavedra Bejarano, Spain
PO-1389
SBRT in all-risk prostate cancer patients, first results from a chilean center with Halcyon linac
Hernan Letelier, Chile
PO-1390
Quantitative Assessment of MR-based IGRT and Adaptation for SABR in Localized Prostate Cancer
Piero Bettoli, Chile
PO-1391
SBRT monotherapy for low and intermediate risk Prostate Cancer. First Chilean experience.
María Fernanda Sánchez, Chile
PO-1392
Hypofractionated prostate radiotherapy: alternate delineation approach vs validated trial protocol
Iosif Strouthos, Cyprus
PO-1393
Adjuvant radiation therapy after radical prostatectomy
VICTOR DUQUE-SANTANA, Spain
PO-1394
Impact of Statin Use on Biochemical Failure following Radical Prostatectomy or Radiation Therapy
Linda Huynh, USA
PO-1395
PSMA-PET management of prostate cancer patients relapsing after RP plus prostate-bed radiotherapy
Valeria Chiofalo, Italy
PO-1396
Quality of life in prostate cancer patients treated with a definitive radiotherapy
Minglun Li, Germany
PO-1397
Early and late treatment toxicity of post-prostatectomy irradiation
Marcin Miszczyk, Poland
PO-1398
assessment of online adaptive MR-Guided prostate SBRT with integrated boost to dominant lesion
Kyle Padgett, USA
PO-1399
Safety and feasibility of PSMA-PET guided SBRT to Oligo-Metastatic Prostate Cancer
Ahmed Gawish, Germany
PO-1400
MR-guided adaptive versus CT-guided SBRT for prostate cancer: where is cost-benefit balance?
Alessandra Castelluccia, Italy
PO-1401
Hypofractionation in localised prostate cancer
Victoria Navarro Aznar, Spain
PO-1402
Postoperative radiatiotherapy in prostate cancer: long-terms results of a single institution
Asunción Hervás, Spain
PO-1403
Adjuvant, Early Salvage and Salvage Radiotherapy after surgery in prostate cancer: survival outcomes
Ilaria Angelicone, Italy
PO-1404
Sbrt in prostate cancer: a feasibility and safety annalysis
Jose Antonio Solis Campos, Chile
PO-1405
Hematological toxicity in pN1 prostate cancer patients treated with extended field irradiation
Charlien Berghen, Belgium
PO-1406
Postoperative hypofractionated RT: toxicity and efficacy in a series of 304 prostate adenocarcinoma
Luca Nicosia, Italy
PO-1407
Two-fraction prostate SABR vs. two-fraction HDR brachytherapy: does dose heterogeneity matter?
Rohann Correa, Canada
PO-1408
Baseline NLR and neutrophil in patients with bladder cancer treated with chemoradiation
Jihane Boustani, France
PO-1409
Radiation therapy for treatment of oligometastatic prostate cancer - 10-year outcomes
Ben Bonebrake, USA
PO-1410
Number of PSMA-PET positive lymph nodes affects outcome in node positive prostate cancer patients
Simon KB Spohn, Germany
PO-1411
Long-term PRQoL outcomes analysis of low-dose-rate brachytherapy prostate cancer
Maria Cerrolaza, Spain
PO-1412
Dose-escalated hypofractionated radiotherapy to 66Gy in localized prostate cancer: long-term results
Antonio Lazo Prados, Spain
PO-1413
Results of a concept-development for a phase III trial on radiotherapy in primary prostate cancer
Simon KB Spohn, Germany
PO-1414
Inter-fraction error analyses and rectal and bladder volume variations using CBCT in prostate cancer
Consuelo Rosa, Italy
PO-1415
DUAL ENERGY COMPUTED TOMOGRAPHY APPLICATIONS FOR PROSTATE RADIOTHERAPY: ADVANTAGES IN TARGET AND OAR CONTOURING
Salvatore Cozzi, Italy
PO-1416
Role of MRI radiomics analysis and Pi-RADS score in prostate cancer.
Antonio Angrisani, Italy
PO-1417
Evaluation of Hyaluronic acid dissolution with hyaluronidase in an in-vitro prostate cancer model
Ben Vanneste, Belgium
PO-1418
Early Outcomes with Linac-based Dose-escalated Prostate SBRT and Real-Time Electromagnetic Tracking
Raffaella Lucchini, Italy
PO-1419
Better neurovascular sparing by daily contouring and plan optimization in MRgRT for prostate cancer
Frederik Teunissen, The Netherlands
PO-1420
Is it possible to deliver on-line MR-guided RT for prostate cancer within a feasible time frame?
Tine Schytte, Denmark
PO-1421
Hypofractionated salvage radiotherapy in patients with biochemical recurrence of prostate cancer
Fabio Matrone, Italy
PO-1422
PSA dynamics forecasts identify tumor recurrence after external radiotherapy for prostate cancer
Nadia Di Muzio, Italy
PO-1423
SBRT for clinically localized prostate cancer in men with hip replacements: a cautionary note
Dylan Conroy, USA
PO-1424
SBRT in patients with oligometastatic renal cell carcinoma: A multi-institutional analysis
Ozan Cem Guler, Turkey
PO-1425
IMRT of the prostate following focal treatment: Analysis of Toxicity.
Alfonso Valcárcel Díaz, Spain
PO-1426